Publication: Survival in adenosquamous cancer of the lung: is it really so unfavorable?
Abstract
Amaç: Bu tek merkezli çalışmada, akciğer adenoskuamöz kanseri (AAK) nedeni ile ameliyat edilmiş hastaların sağkalım oranları ile adenokarsinom veya skuamöz hücreli karsinom nedeni ile ameliyat edilmiş hastaların sağkalım oranları arasında anlamlı bir farklılık olup olmadığı araştırıldı. Çalışmaplanı: Ocak 2002 - Ocak 2011 tarihleri arasında hastanemizde küçük hücreli dışı akciğer kanseri nedeni ile ameliyat edilen toplam 2203 hasta (1977 erkek, 226 kadın; ort. yaş 57.8±34.9 yıl; dağılım 22-86 yıl) patolojik tanı, sağkalım ve tümör evresi yönünden retrospektif olarak analiz edildi. Bul gu lar: Patolojik analiz sonucunda, 2203 hastanın 46sında (%2.1) adenoskuamöz kanser tanısı doğrulandı. Ortanca sağkalım süresi adenokarsinom için 53.6 ay (dağılım 21.1-68.2 ay), skuamöz hücreli karsinom için 48.1 ay (dağılım 24.4-66.9 ay) ve AAK için 27.9 ay idi (dağılım 10.7-44.6 ay) (p=0.026). Ortanca sağkalım süresi adenokarsinom predominansı olan hasta grubunda 21.6 ay, skuamöz hücreli karsinom predominansı olan hasta grubunda 21.4 ay, kodominant hücre dizisi olan hasta grubunda 37.8 ay idi (p=0.007). So nuç: Çalışmamızda, AAK hastalarının sağkalım oranı skuamöz hücreli karsinom veya adenokarsinom hastalarınınkinden daha düşük idi. Cerrahi rezeksiyon sonrası adjuvan kemoradyoterapinin genel sağkalım oranlarını iyileştirip iyileştirmediğini araştıracak ileri klinik çalışmalar gereklidir.
Background: This single-center study aims to investigate whether a significant difference exits between the survival rates of patients operated for adenosquamous cancer of the lung (ASCL) and patients operated for adenocarcinoma or squamous cell carcinoma. Methods: A total of 2,203 patients (1,977 males, 226 females; mean age 57.8±34.9 years; range 22 to 86 years) operated for non-small cell lung cancer in our hospital between January 2002 and January 2011 were retrospectively analyzed for pathological diagnosis, survival, and tumor staging. Results: As a result of pathological analysis, the diagnosis of adenosquamous cancer was confirmed in 46 out of 2,203 (2.1%) patients. The median survival time was 53.6 months (range 21.1 to 68.2 months) for adenocarcinoma, 48.1 months (range 24.4 to 66.9 months) for squamous cell cancer, and 27.9 months (range 10.7 to 44.6 months) for ASCL (p=0.026). The median survival time was 21.6 months in the group of patients with predominating adenocarcinoma, 21.4 months in the group of patients with predominating squamous cell carcinoma, and 37.8 months in the group of patients with codominant cell lines (p=0.007). Conclusion: In our study, the survival rate of ASCL patients was lower than that of patients with squamous cell carcinoma or adenocarcinoma. Further clinical studies are needed to investigate whether adjuvant chemoradiotherapy following surgical resection improves overall survival rates.
Background: This single-center study aims to investigate whether a significant difference exits between the survival rates of patients operated for adenosquamous cancer of the lung (ASCL) and patients operated for adenocarcinoma or squamous cell carcinoma. Methods: A total of 2,203 patients (1,977 males, 226 females; mean age 57.8±34.9 years; range 22 to 86 years) operated for non-small cell lung cancer in our hospital between January 2002 and January 2011 were retrospectively analyzed for pathological diagnosis, survival, and tumor staging. Results: As a result of pathological analysis, the diagnosis of adenosquamous cancer was confirmed in 46 out of 2,203 (2.1%) patients. The median survival time was 53.6 months (range 21.1 to 68.2 months) for adenocarcinoma, 48.1 months (range 24.4 to 66.9 months) for squamous cell cancer, and 27.9 months (range 10.7 to 44.6 months) for ASCL (p=0.026). The median survival time was 21.6 months in the group of patients with predominating adenocarcinoma, 21.4 months in the group of patients with predominating squamous cell carcinoma, and 37.8 months in the group of patients with codominant cell lines (p=0.007). Conclusion: In our study, the survival rate of ASCL patients was lower than that of patients with squamous cell carcinoma or adenocarcinoma. Further clinical studies are needed to investigate whether adjuvant chemoradiotherapy following surgical resection improves overall survival rates.